急性髓系白血病中的异基因干细胞移植。
Allogeneic stem cell transplantation in acute myeloid leukemia.
作者信息
Ali Natasha, Adil Salman Naseem, Shaikh Mohammad Usman, Masood Nehal
机构信息
Department of Pathology and Microbiology;
出版信息
Hematol Rep. 2012 Nov 19;4(4):e25. doi: 10.4081/hr.2012.e25. Epub 2012 Nov 29.
Abstract
We report a case series of 12 patients with acute myeloid leukemia who underwent allogeneic stem cell transplant with a matched related donor. Male to female ratio was 1:1. The main complication post-transplant was graft-versus-host disease (n=7 patients). Transplant-related mortality involved one patient; cause of death was multi-organ failure. After a median follow up of 36.0±11.3 months, overall survival was 16%.
摘要
我们报告了一组12例接受同胞全相合异基因造血干细胞移植的急性髓系白血病患者的病例系列。男女比例为1:1。移植后主要并发症为移植物抗宿主病（7例患者）。移植相关死亡率为1例患者；死亡原因是多器官功能衰竭。中位随访36.0±11.3个月后，总生存率为16%。
相似文献
1
Allogeneic stem cell transplantation in acute myeloid leukemia.
Hematol Rep. 2012 Nov 19;4(4):e25. doi: 10.4081/hr.2012.e25. Epub 2012 Nov 29.
2
Haploidentical unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT.
Haematologica. 2019 Mar;104(3):524-532. doi: 10.3324/haematol.2017.187450. Epub 2018 Oct 25.
3
The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study.
Haematologica. 2012 Jan;97(1):21-9. doi: 10.3324/haematol.2011.051714. Epub 2011 Sep 20.
4
Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Haematologica. 2018 Aug;103(8):1317-1328. doi: 10.3324/haematol.2018.189258. Epub 2018 May 10.
5
Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party.
J Hematol Oncol. 2017 Jan 24;10(1):31. doi: 10.1186/s13045-016-0389-4.
6
Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Cancer. 2014 Mar 15;120(6):855-63. doi: 10.1002/cncr.28498. Epub 2013 Dec 10.
7
Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Biol Blood Marrow Transplant. 2015 Nov;21(11):2008-16. doi: 10.1016/j.bbmt.2015.07.019. Epub 2015 Jul 26.
8
Second allogeneic hematopoietic stem cell transplantation as treatment for leukemia relapsing following a first transplant.
Bone Marrow Transplant. 2000 Jan;25(1):41-5. doi: 10.1038/sj.bmt.1702101.
9
Autologous blood cell transplantation versus HLA-identical sibling transplantation for acute myeloid leukemia in first complete remission: a registry study from the Center for International Blood and Marrow Transplantation Research.
Haematologica. 2013 Feb;98(2):185-92. doi: 10.3324/haematol.2012.062059. Epub 2012 Sep 14.
10
Graft-versus-host disease after radiation therapy in patients who have undergone allogeneic stem cell transplantation: two case reports.
J Med Case Rep. 2016 Jul 28;10:209. doi: 10.1186/s13256-016-0999-z.
本文引用的文献
1
Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure.
J Clin Oncol. 2010 Aug 10;28(23):3730-8. doi: 10.1200/JCO.2010.28.8852. Epub 2010 Jul 12.
2
The stem cell transplant program in Pakistan--the first decade.
Bone Marrow Transplant. 2008 Aug;42 Suppl 1:S114-S117. doi: 10.1038/bmt.2008.137.
3
Peripheral blood progenitor cell or bone marrow transplantation: controversy remains.
Curr Opin Oncol. 2008 Mar;20(2):220-6. doi: 10.1097/CCO.0b013e3282f5100b.
4
Management of acute myeloid leukaemia--5 years experience at Armed Forces Bone Marrow Transplant Centre, Rawalpindi.
J Pak Med Assoc. 2007 Sep;57(9):434-9.
5
EBMT activity survey 2004 and changes in disease indication over the past 15 years.
Bone Marrow Transplant. 2006 Jun;37(12):1069-85. doi: 10.1038/sj.bmt.1705377.
6
Geographic differences in the incidence of cytogenetic abnormalities of acute myelogenous leukemia (AML) in Spain.
Leuk Res. 2006 Aug;30(8):943-8. doi: 10.1016/j.leukres.2005.12.025. Epub 2006 Feb 28.
7
Age and acute myeloid leukemia.
Blood. 2006 May 1;107(9):3481-5. doi: 10.1182/blood-2005-09-3724. Epub 2006 Feb 2.
8
Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: an intent-to-treat long-term analysis of the BGMT experience.
J Clin Oncol. 2005 Oct 20;23(30):7676-84. doi: 10.1200/JCO.2005.02.5940. Epub 2005 Sep 26.
9
Clinical impact of graft-versus-host disease against leukemias not in remission at the time of allogeneic hematopoietic stem cell transplantation from related donors. The Japan Society for Hematopoietic Cell Transplantation Working Party.
Bone Marrow Transplant. 2004 Oct;34(8):711-9. doi: 10.1038/sj.bmt.1704659.
10
Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial.
Blood. 2003 Aug 15;102(4):1232-40. doi: 10.1182/blood-2002-12-3714. Epub 2003 Apr 24.
Zotero 插件